Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 2,500 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $12.95, for a total value of $32,375.00. Following the completion of the transaction, the chief financial officer directly owned 119,010 shares of the company’s stock, valued at $1,541,179.50. The trade was a 2.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kory James Wentworth also recently made the following trade(s):

• On Tuesday, March 10th, Kory James Wentworth sold 11,388 shares of Entrada Therapeutics stock. The stock was sold at an average price of $13.02, for a total value of $148,271.76.
• On Monday, March 9th, Kory James Wentworth sold 5,089 shares of Entrada Therapeutics stock. The shares were sold at an average price of $13.00, for a total value of $66,157.00.
• On Wednesday, March 4th, Kory James Wentworth sold 7,988 shares of Entrada Therapeutics stock. The shares were sold at an average price of $12.25, for a total value of $97,853.00.

Entrada Therapeutics Stock Down 2.4%

Shares of TRDA stock opened at $13.15 on Friday. The stock has a market cap of $503.38 million, a P/E ratio of -3.80 and a beta of -0.15. Entrada Therapeutics, Inc. has a fifty-two week low of $4.93 and a fifty-two week high of $13.66. The business has a fifty day simple moving average of $11.76 and a 200-day simple moving average of $9.60.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) EPS for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.38. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. The firm had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $7.41 million. On average, sell-side analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on TRDA. Wall Street Zen cut shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a research note on Friday, March 27th. Cantor Fitzgerald assumed coverage on Entrada Therapeutics in a report on Wednesday. They set an “overweight” rating on the stock. Guggenheim raised Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Finally, Oppenheimer assumed coverage on Entrada Therapeutics in a report on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.50.

Hedge Funds Weigh In On Entrada Therapeutics

A number of institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC lifted its stake in shares of Entrada Therapeutics by 9.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock valued at $176,000 after buying an additional 1,560 shares during the period. Alliancebernstein L.P. raised its holdings in Entrada Therapeutics by 7.1% in the 3rd quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock valued at $141,000 after acquiring an additional 1,620 shares during the last quarter. Great Lakes Advisors LLC boosted its holdings in shares of Entrada Therapeutics by 5.5% during the fourth quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock worth $445,000 after purchasing an additional 2,239 shares during the last quarter. Intech Investment Management LLC boosted its holdings in shares of Entrada Therapeutics by 15.7% during the second quarter. Intech Investment Management LLC now owns 17,702 shares of the company’s stock worth $119,000 after purchasing an additional 2,397 shares during the last quarter. Finally, Quadrature Capital Ltd grew its position in shares of Entrada Therapeutics by 13.5% in the fourth quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock valued at $209,000 after purchasing an additional 2,424 shares during the period. Institutional investors and hedge funds own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.